Executive Steering Committee Elections 2026

Nominee Name: Mandy Gervasio
Current Position/Title: Head of QA Compliance
BioMaP-Consortium Member Organization: Virginia Commonwealth University - Medicines for All Institute
ESC Seat Applying for: Regulatory, Quality, and Policy

Please describe how your background, training, and experience would support your ability to serve in a governance role on the Executive Steering Committee.

Over nearly two decades, I have served in quality and compliance leadership roles across biotechnology, pharmaceutical, and contract development and manufacturing organizations supporting research, development, clinical operations, commercial manufacturing, and post-market activities. Throughout my career, I have built Quality Management Systems, established governance frameworks, led inspection readiness initiatives, strengthened quality risk management programs, and partnered with executive leadership to integrate quality into organizational strategy.

Today, as Head of Quality for Medicines for All Institute, I am leading the development of the quality operating model supporting a new API manufacturing capability. This work requires close collaboration across research, manufacturing, engineering, facilities, regulatory, and executive leadership to build quality into the organization from the outset.

My experience has reinforced that effective governance depends not only on technical expertise, but also on collaboration, transparency, thoughtful decision-making, and the ability to translate complex regulatory expectations into practical organizational strategies. I believe these experiences have prepared me to contribute meaningfully to the Executive Steering Committee while supporting BioMaP's mission of advancing innovation through collaboration.

Please describe the relevant experience, expertise, and perspective you would bring to the ESC seat you selected.

The regulatory and quality landscape is evolving rapidly alongside advances in manufacturing, digital technologies, and new approaches to product development. I believe one of the greatest opportunities for our profession is helping organizations translate evolving regulatory expectations into governance structures, operating models, and practical implementation strategies that enable innovation while maintaining public trust.

My perspective is rooted in systems thinking. Rather than viewing quality solely as a compliance function, I see it as an organizational capability that strengthens governance, supports informed decision-making, and creates resilient systems capable of adapting to change.

If selected, I would support the committee by helping develop practical regulatory intelligence, educational programming, expert discussions, and collaborative forums that connect regulatory developments with real-world implementation. I value bringing together perspectives from industry, academia, manufacturing, and research because many of our profession's most valuable insights emerge through collaboration.

I believe the future of quality leadership lies not only in ensuring compliance, but in building the governance, systems, and collaborative capabilities that enable scientific innovation to advance responsibly. I would be honored to contribute that perspective in support of the BioMaP Consortium and its members.